WO1990005186A1 - Somatotropin expression using a serratia promoter - Google Patents
Somatotropin expression using a serratia promoter Download PDFInfo
- Publication number
- WO1990005186A1 WO1990005186A1 PCT/US1989/003854 US8903854W WO9005186A1 WO 1990005186 A1 WO1990005186 A1 WO 1990005186A1 US 8903854 W US8903854 W US 8903854W WO 9005186 A1 WO9005186 A1 WO 9005186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- somatotropin
- expression
- promoter
- vector
- recombinant dna
- Prior art date
Links
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 17
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract 10
- 241000607720 Serratia Species 0.000 title description 3
- 241000607715 Serratia marcescens Species 0.000 claims abstract description 14
- 108010006025 bovine growth hormone Proteins 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 4
- 108020004511 Recombinant DNA Proteins 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 25
- 239000013604 expression vector Substances 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 7
- 239000013598 vector Substances 0.000 description 27
- 241000588724 Escherichia coli Species 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102100038803 Somatotropin Human genes 0.000 description 7
- 239000000499 gel Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- PLVPPLCLBIEYEA-WAYWQWQTSA-N (z)-3-(1h-indol-3-yl)prop-2-enoic acid Chemical compound C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229920006063 Lamide® Polymers 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000008176 mammary development Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 101150002764 purA gene Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 101150079396 trpC2 gene Proteins 0.000 description 1
- 101150006320 trpR gene Proteins 0.000 description 1
- 101150108727 trpl gene Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
Definitions
- This invention relates to methods for expressing mammalian somatotropins. More specifically, the invention relates to expres ⁇ sing bovine somatotropin in an E. coli host with a spontaneous runaway expression vector comprising a promoter from Serratia marcescens . BACKGROUND OF THE INVENTION
- Some heterologous polypeptides, including bovine somatotropin (bSt) are difficult to express in most E. coli expression systems. Modifications within the first 4 codons of the cDNA encoding the bSt structural gene result in increased levels of bSt expression when these modified cDNAs are expressed in a pBR322-related vector. These modified cDNAs are expressed at even higher levels when placed in a spontaneous runaway expression vector (PCT patent application PCT/US 88/00328, incorporated herein by reference).
- Bovine somatotropin is a mixture of heterogeneous proteins, the amino acid sequences of which are known (Paladini, A.C., et al., Molecular Biology of Growth Hormone, CRC Reviews in Biochem. , 15(l):25-56 (1983)). The naturally occurring mixtures have been purified from pituitary glands of cattle. The commercial potential for using bSt for promoting growth and lactation is well recognized and documented by biological studies on both dairy and feed cattle (Eppard, P.J.
- Recombinant bovine somatotropin can be produced in transformed microorganisms using a variety of recombinant genetic plasmids (see, e.g., Seeburg, P.H. , et al., "Efficient Bacterial Expression of Bovine and Porcine Growth Hormones," DNA, 2:37-45 (1983); European Patent Application 47 600; United Kingdom Patent Application, GB 2073245A; Schoner, B.E., et al., Role of mRNA Translational Efficiency in Bovine Growth Hormone Expression in Escherichia coli, PNAS USA, 81:5403-5407 (1984); European Patent Application 103 395; and European Patent Application 111 814).
- G.F. Miozzari and C. Yanofsky, Nature, 276, pp. 684-89 (1978) refer to cloning and sequencing the regulatory region, including the promoter and operator, of the trp operon of Serratia marcescens .
- B.P. Nichols and C. Yanofsky, Meth. Enzym., 101, pp. 155-64 (1983) refer to expression plasmids containing the Serratia marcescens trp promoter and their use for overproduction of trp operon polypeptides in E. coli .
- German patent application 3247922-A refer to an expression plasmid consist ⁇ ing of the promoter/operator region of the Serratia marcescens trp operon and a synthetic ribosome binding site ligated into pBR322 and its use for producing leukocyte-type interferons.
- the instant invention relates to vectors comprising the Serratia marcescens trp promoter useful for expressing somatotropins.
- the preferred expression vectors also comprise a synthetically produced, AT-rich ribosome binding site and a spontaneous runaway vector comprising dual origins of replication, particularly well suited for expressing bSt and porcine somatotropin (pSt) , more particularly, bSt.
- pSt porcine somatotropin
- the invention also relates to methods for producing somatotro ⁇ pins, particularly bSt and pSt, using these vectors.
- the preferred DNA sequence encoding bSt contains a single change wherein the fourth codon for alanine is changed from GCC to GCT (PCT patent application PCT US 88/00328).
- expression vectors that contain, at a minimum, a strong promoter to direct mRNA transcrip ⁇ tion, a ribosome binding site for translational initiation, and, usually, a transcription terminator (collectively, “the expression control sequences") all of which are operatively linked to the desired gene.
- the term "operatively linked” includes having an appropriate start signal in front of the gene encoding the desired product and maintaining the correct reading frame to permit expres ⁇ sion of the inserted gene under the control of the expression control sequences and synthesis of the desired product encoded for by that gene.
- the promoter chosen to direct the synthesis of the product should be regulated in such a way that cell growth can reach high densities before the promoter is induced.
- regulatory regions suitable for this purpose are the promoter and operator region of the E. coli tryptophan biosynthetic pathway (.trp promoter) and the leftward promoter of phage lambda (PL .
- the trp promoter is repressed in the presence of tryptophan and can be induced by tryptophan starvation or by the addition of the inducer indole acrylic acid (Yanofsky, C, et al., J. Bacteriol., 158:1018-1024 (1984)).
- Most preferred are expression vectors having restriction enzyme sites for insertion of genes to be expressed at an appropriate distance from the Shine- Dalgarno sequence.
- the preferred DNA coding sequence of the present invention is the bSt cDNA sequence modified at the 4th codon by changing GCC to GCT.
- the preferred vector of this invention comprises a pBR322 replicon which expresses the modified bovine somatotropin at particularly high levels.
- Vectors other than pBR322- derived plasmids can be used.
- pBR322 has a ColEl replicon.
- Other plasmids with ColEl replicons include pKC7, pAT153, and pBR325. They differ from pBR322 only in their drug resistance makers.
- vectors include pACYC184 (pl5A replicon) , pN01523 (pMBl replicon), pLG338 (pSClOl replicon), and pBEU50 (Rl replicon) (Maniatis; Pouvels, P.H. , et al, Cloning Vectors , Elsevier, New York 1985). Also useful are pUC19 (Yanisch-Perron, C, et al, Gene, 33:103-119 1985) and pHC314 (Boros, I., et al, Gene 30:257-260 1984).
- pURA type vectors Rl and ColEl replicon; PCT/US 88/00328.
- the isolation and purification of mammalian somatotropins from recombinant microorganisms is known (see, e.g., U.S. Pat. Nos. 4,511,502, 4,512,922 and 4,518,526; European Patent Application 131,843; and Schoner, R.G., et al., Isolation and purification of protein granules from E. coli cells overproducing BGH, Bio-Technology, 3:151-154).
- the process involves lysing the recombinant microorganisms, selective centrifugation, reshuffling of any non-native disulfide bonds to the native con ⁇ figuration and column chromatography.
- EXAMPLE 1 Construction of a Plasmid for bSt Expression Com ⁇ prising the Serratia marcescens trp Promoter 1. Assembly and Introduction of the Serratia marcescens trp promoter into the pURA-4 vector.
- oligonucleotides are assembled into a double stranded DNA block as shown below.
- the oligonucleotides are purified by cutting the appropriate band from a 20% acr lamide/urea gel. The bands are visualized by il- luminating the gel with short wave UV light on a thin layer silica gel GF (920 x 20 cm). The oligonucleotides are removed form the gel by soaking overnight in 0.5 M ammonium acetate and 1 mM EDTA at 37°C. The oligonucleotides are desalted using Waters Sep-Pak c-18 columns. Oligonucleotides 2 and 4 are labeled with - ⁇ 'P- TP as described in PCT/US 88/00328.
- Oligonucleotides are hybridized to their comple ⁇ ments (i.e., 1/4, and 2/3). The hybridized oligonucleotides are then ligated together, and purified from a 10% acrylamide gel after autoradiography as previously described in PCT/US 88/00328.
- the sequence of the double-stranded oligonucleotide block is shown below: EcoRI 5' AATTCACGCTGATCGCTAAAACATTGTGCAAAAAGAGGGTTGACTTTGCCTTCGCGAACCAG GTGCGACTAGCGATTTTGTAACACGTTTTTCTCCCAACTGAAACGGAAGCGCTTGGAC +1 TTAACTAGTACACAATCTAGATAAAAAGGGTAT AATTGATCATGTG ⁇ AGATCTATTTTTCCCATAGC
- the oligonucleotide is designed to insert into the unique EcoRI and Clal restriction sites of the pURA-4 vector (PCT/US 88/00328) .
- the fragment also contains a Xbal site which is unique for the vector and allows the insertion of ribosome binding sites as an Xbal/Clal fragment.
- the vector is digested with EcoRI and Clal. The digestion is run on an acrylamide gel and the large vector fragment (5.5 Kb) is cut out and isolated using Geneclean (available from BIO 101 Inc., P.O. Box 2284, La Jolla, CA). This digestion removes the E. coli trp promoter and the trpL ribosome binding site.
- Geneclean available from BIO 101 Inc., P.O. Box 2284, La Jolla, CA. This digestion removes the E. coli trp promoter and the trpL ribosome binding site.
- the vector fragment is ligated with the S . marcescens trp promoter fragment from above, and used to transform competent cells of E. coli MC 1000 (available in the Experiments with Gene Fusions Strain Kit, Cold Spring Harbor Laboratory, Cold Spring Harbor New York) .
- Vector DNA is isolated from transformed cells and DNA is prepared (Maniatis). The vectors are confirmed by DNA sequencing using Sequenase (United States Biochemical Corp. Cleve ⁇ land, Ohio). One confirmed candidate is designated pURA-Sm/m4. 2. Introduction of a ribosome binding site into the pURA-Sm/M4 Vector. A ribosome binding site is designed based on the AT and trp2 ribosome binding sites described in copending U.S. patent application S.N. 166,882, filed 11 March 1988, and incorporated herein by re ⁇ ference.
- TAT The ribosome binding site (rbs) referred to as TAT contains the upstream sequence found in the AT-rich rbs and the Clal site as found in the Trp2 rbs.
- the two oligonucleotides are synthesized, and isolated as previously described. The two oligonucleotides are then hybridized to form the following fragment:
- This fragment is designed to be inserted into the restriction site of the pURA-SM/M4 vector produced by digestion with Xbal and Clal.
- the pURA-Sm/M4 vector is digested with Xbal and Clal and the large vector fragment is purified as described above.
- the purified vector fragment is ligated to the TAT rbs and the ligation product is used to transform competent cells of E. coli MC1000.
- the resultant vector is sequenced for confirmation and is designated pURA-Sm/TAT/- M4.
- EXAMPLE 2 BSt Expression Using an Expression Vector Comprising a Serratia marcescens trp Promoter
- the pURA-Sm/TAT/M4 vector from Example 1 is used to transformed competent cells of BST-1C (PCT/US 88/00328) .
- the induction protocol was previously described (PCT/US 88/00328).
- the results of scanning of Coomassie stained protein gel showed the vector to express rbSt at a level of about 20% of the total protein.
- EXAMPLE 3 Porcine and Ovine Somatotropin Expression Using an Expression Vector Comprising a Serratia marcescens trp Promoter
- the porcine or ovine somatotropin gene can also be expressed under the control of the Serratia marces ⁇ cens trp promoter.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Provided are expression vectors and methods for expressing somatotropins comprising a Serratia marcescens trp promoter and a gene encoding said somatotropin operatively linked thereto.
Description
SOMATOTROPIN EXPRESSION USING A SERRATIA PROMOTER FIELD OF INVENTION
This invention relates to methods for expressing mammalian somatotropins. More specifically, the invention relates to expres¬ sing bovine somatotropin in an E. coli host with a spontaneous runaway expression vector comprising a promoter from Serratia marcescens . BACKGROUND OF THE INVENTION Some heterologous polypeptides, including bovine somatotropin (bSt) , are difficult to express in most E. coli expression systems. Modifications within the first 4 codons of the cDNA encoding the bSt structural gene result in increased levels of bSt expression when these modified cDNAs are expressed in a pBR322-related vector. These modified cDNAs are expressed at even higher levels when placed in a spontaneous runaway expression vector (PCT patent application PCT/US 88/00328, incorporated herein by reference).
Bovine somatotropin is a mixture of heterogeneous proteins, the amino acid sequences of which are known (Paladini, A.C., et al., Molecular Biology of Growth Hormone, CRC Reviews in Biochem. , 15(l):25-56 (1983)). The naturally occurring mixtures have been purified from pituitary glands of cattle. The commercial potential for using bSt for promoting growth and lactation is well recognized and documented by biological studies on both dairy and feed cattle (Eppard, P.J. and Bauman, D.E., The Effect of Long-Ter Administra¬ tion of Growth Hormone on Performance of Lactating Dairy Cows; and Bauman, D.E., Effect of Growth Hormone on Growth Rates and Mammary Development of Ruminants, Proc. 1984 Cornell Nutrition Conference for Feed Manufacturers, pp. 5-17, published by Cornell University, Ithaca, New York) .
Recombinant bovine somatotropin (rBSt) can be produced in transformed microorganisms using a variety of recombinant genetic plasmids (see, e.g., Seeburg, P.H. , et al., "Efficient Bacterial Expression of Bovine and Porcine Growth Hormones," DNA, 2:37-45 (1983); European Patent Application 47 600; United Kingdom Patent Application, GB 2073245A; Schoner, B.E., et al., Role of mRNA Translational Efficiency in Bovine Growth Hormone Expression in Escherichia coli, PNAS USA, 81:5403-5407 (1984); European Patent
Application 103 395; and European Patent Application 111 814). These documents relate to the insertion or deletion of bases at the 5' end of the bSt gene creating a protein different from the naturally- occurring polypeptide, or to changes in the bSt cDNA to maximize preferred codons and to reduce secondary structure in the mRNA, or to the use of a runaway plasmid to enhance expression. On the other hand, the instant invention teaches the use of the trp promoter from Serratia marcescens to produce somatotropins, and in particular bSt, at a high level. Methods of culturing and fermenting transformed microorganisms expressing bSt are also referred to in the above-cited documents.
Purification of biologically active rBSt from transformed cells has also been described previously (see, e.g., U.S. patent Nos. 4,511,502, 4,511,503, 4,512,922 and 4,518,526; European Patent Application 131 843; and, Schoner, R.G. , et al. , "Isolation and Purification of Protein Granules from E. coli Cells Overproducing BSt," Bio-Tech., 3:151-154 (1985)).
Nicoles and Yanofsky (Meth. Enzym. , 101, p. 155 (1983) have demonstrated that the Serratia marcescens trp promoter is functional in Escherichia coli . PCT/US 88/00328 describes the expression of an rbSt cDNA gene vising a spontaneous runaway vector and the tryptophan promoter of E. coli in an E. coli host. The present invention relates to the use of the Serratia marcescens trp promoter in this expression system. INFORMATION DISCLOSURE STATEMENT
G.F. Miozzari and C. Yanofsky, Nature, 276, pp. 684-89 (1978) refer to cloning and sequencing the regulatory region, including the promoter and operator, of the trp operon of Serratia marcescens . B.P. Nichols and C. Yanofsky, Meth. Enzym., 101, pp. 155-64 (1983) refer to expression plasmids containing the Serratia marcescens trp promoter and their use for overproduction of trp operon polypeptides in E. coli .
J.N. Hope, et al, J. Biol. Chem., 261, pp. 7663-68 (1986) refer to cloning and expressing the gene encoding E. coli ribokinase downstream from the Serratia marcescens trp promoter on a multicopy plasmid in an E. coli host.
J. Stader, et al, J. Bact. , 166, pp. 244-52 (1986) refer to cloning and expressing an E. coli membrane protein (MotB) downstream
from the Serratia marcescens trp promoter in an E. coli host. M.L. Wilson and R.M. MacNab, J. Bact., 170, pp. 588-97 (1988) refer to expression of the MotA E. coli membrane protein in and E. coli host under control of the Serratia marcescens trp promoter. E. Dworkin-Rastl, et al, Gene, 21, pp. 237-48 (1983) and German patent application 3247922-A refer to an expression plasmid consist¬ ing of the promoter/operator region of the Serratia marcescens trp operon and a synthetic ribosome binding site ligated into pBR322 and its use for producing leukocyte-type interferons. SUMMARY OF THE INVENTION
The instant invention relates to vectors comprising the Serratia marcescens trp promoter useful for expressing somatotropins.
More particularly, the preferred expression vectors also comprise a synthetically produced, AT-rich ribosome binding site and a spontaneous runaway vector comprising dual origins of replication, particularly well suited for expressing bSt and porcine somatotropin (pSt) , more particularly, bSt.
The invention also relates to methods for producing somatotro¬ pins, particularly bSt and pSt, using these vectors. The preferred DNA sequence encoding bSt contains a single change wherein the fourth codon for alanine is changed from GCC to GCT (PCT patent application PCT US 88/00328).
DETAILED DESCRIPTION OF THE INVENTION Generally, the definitions of nomenclature and descriptions of general laboratory procedures used in this invention can be found in Maniatis, T. et al., Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982. The manual is hereinafter referred to as "Maniatis" and is incorporated herein by reference. All restriction endonuclease and other DNA modifying enzymes are commercially available and are used according to the manufacturer's instructions.
For high level expression of a desired cloned gene in a pro- karyotic system, it is essential to construct expression vectors that contain, at a minimum, a strong promoter to direct mRNA transcrip¬ tion, a ribosome binding site for translational initiation, and, usually, a transcription terminator (collectively, "the expression control sequences") all of which are operatively linked to the
desired gene. The term "operatively linked" includes having an appropriate start signal in front of the gene encoding the desired product and maintaining the correct reading frame to permit expres¬ sion of the inserted gene under the control of the expression control sequences and synthesis of the desired product encoded for by that gene.
Since the accumulation of large amounts of a gene product often inhibits cell growth and sometimes causes cell death, the promoter chosen to direct the synthesis of the product should be regulated in such a way that cell growth can reach high densities before the promoter is induced. Examples of regulatory regions suitable for this purpose are the promoter and operator region of the E. coli tryptophan biosynthetic pathway (.trp promoter) and the leftward promoter of phage lambda (PL . The trp promoter is repressed in the presence of tryptophan and can be induced by tryptophan starvation or by the addition of the inducer indole acrylic acid (Yanofsky, C, et al., J. Bacteriol., 158:1018-1024 (1984)). Most preferred are expression vectors having restriction enzyme sites for insertion of genes to be expressed at an appropriate distance from the Shine- Dalgarno sequence.
To synthesize intracellularly a protein encoded by a eukaryotic gene from its cDNA sequence in E. coli and other prokaryotes, it is expedient to remove the 5' untranslated region and the sequence coding for the signal peptide and to supply an initiation codon for translation initiation of the sequence coding for the mature protein. It may also be necessary to replace some of the coding sequence for the mature protein with chemically synthesized oligonucleotides to maximize translation efficiency. The preferred DNA coding sequence of the present invention is the bSt cDNA sequence modified at the 4th codon by changing GCC to GCT. The preferred vector of this invention comprises a pBR322 replicon which expresses the modified bovine somatotropin at particularly high levels. Vectors other than pBR322- derived plasmids can be used. pBR322 has a ColEl replicon. Other plasmids with ColEl replicons include pKC7, pAT153, and pBR325. They differ from pBR322 only in their drug resistance makers. Other useful vectors include pACYC184 (pl5A replicon) , pN01523 (pMBl replicon), pLG338 (pSClOl replicon), and pBEU50 (Rl replicon) (Maniatis; Pouvels, P.H. , et al, Cloning Vectors , Elsevier, New York
1985). Also useful are pUC19 (Yanisch-Perron, C, et al, Gene, 33:103-119 1985) and pHC314 (Boros, I., et al, Gene 30:257-260 1984). Most preferred are pURA type vectors (Rl and ColEl replicon; PCT/US 88/00328). As noted above, the isolation and purification of mammalian somatotropins from recombinant microorganisms is known (see, e.g., U.S. Pat. Nos. 4,511,502, 4,512,922 and 4,518,526; European Patent Application 131,843; and Schoner, R.G., et al., Isolation and purification of protein granules from E. coli cells overproducing BGH, Bio-Technology, 3:151-154). In summary, the process involves lysing the recombinant microorganisms, selective centrifugation, reshuffling of any non-native disulfide bonds to the native con¬ figuration and column chromatography.
A comparison between the sequence of the S . marcescens and the E. coli trp promoters as taken from Nicoles and Yanofsky, supra, is shown below. The sequence is from the -60 nucleotide to the -1 nucleotide of the promoter.
5. marcescens CTAAAACATTG TGCAAAAAGAG GGTTGACTTTG CCTTCGCGAAC CAGTTAACTAG TACAC
E. coli
GGCAAATATTC TTGAAATGAGC TGTTGACAATT AATCATCGAAC TAGTTAACTAG TACGC
Although there are substantial differences in the nucleotide sequences, the operator site is conserved between these two promoters and it has been shown that the S . marcescens promoter can be regu¬ lated by the trpR repressor protein (Manson and Yanofsky, J. Bact. , 126, p. 697 (1976)). EXAMPLE 1. Construction of a Plasmid for bSt Expression Com¬ prising the Serratia marcescens trp Promoter 1. Assembly and Introduction of the Serratia marcescens trp promoter into the pURA-4 vector.
The following four oligonucleotides are synthesized according to the method set forth in PCT application PCT/US 88/00328.
1 5'- AATTCACGCTGATCGCTAAAACATTGTGCAAAAAGAGGGTTGACTTT
2 5'- GCCTTCGCGAACCAGTTAACTAGTACACAATCTAGATAAAAAGGGTAT
• 3 5'- CGATACCCTTTTTATCTAGATTGTGTACTAGTTAACTGGTTCGCGAAGGC
4 5' - AAAGTCAACCCTCT TTTGCACAATGTTTTAGCGATCAGCGTG
These oligonucleotides are assembled into a double stranded DNA block as shown below.
1 2 5' 5'
4 3
The oligonucleotides are purified by cutting the appropriate band from a 20% acr lamide/urea gel. The bands are visualized by il- luminating the gel with short wave UV light on a thin layer silica gel GF (920 x 20 cm). The oligonucleotides are removed form the gel by soaking overnight in 0.5 M ammonium acetate and 1 mM EDTA at 37°C. The oligonucleotides are desalted using Waters Sep-Pak c-18 columns. Oligonucleotides 2 and 4 are labeled with -^'P- TP as described in PCT/US 88/00328. Oligonucleotides are hybridized to their comple¬ ments (i.e., 1/4, and 2/3). The hybridized oligonucleotides are then ligated together, and purified from a 10% acrylamide gel after autoradiography as previously described in PCT/US 88/00328.
The sequence of the double-stranded oligonucleotide block is shown below: EcoRI 5' AATTCACGCTGATCGCTAAAACATTGTGCAAAAAGAGGGTTGACTTTGCCTTCGCGAACCAG GTGCGACTAGCGATTTTGTAACACGTTTTTCTCCCAACTGAAACGGAAGCGCTTGGAC +1 TTAACTAGTACACAATCTAGATAAAAAGGGTAT AATTGATCATGTGΓΓAGATCTATTTTTCCCATAGC
Xbal Clal
The oligonucleotide is designed to insert into the unique EcoRI and Clal restriction sites of the pURA-4 vector (PCT/US 88/00328) . The fragment also contains a Xbal site which is unique for the vector and allows the insertion of ribosome binding sites as an Xbal/Clal fragment.
To clone this fragment into the pURA-4 vector, the vector is digested with EcoRI and Clal. The digestion is run on an acrylamide gel and the large vector fragment (5.5 Kb) is cut out and isolated using Geneclean (available from BIO 101 Inc., P.O. Box 2284, La Jolla, CA). This digestion removes the E. coli trp promoter and the trpL ribosome binding site. The vector fragment is ligated with the
S . marcescens trp promoter fragment from above, and used to transform competent cells of E. coli MC 1000 (available in the Experiments with Gene Fusions Strain Kit, Cold Spring Harbor Laboratory, Cold Spring Harbor New York) . Vector DNA is isolated from transformed cells and DNA is prepared (Maniatis). The vectors are confirmed by DNA sequencing using Sequenase (United States Biochemical Corp. Cleve¬ land, Ohio). One confirmed candidate is designated pURA-Sm/m4. 2. Introduction of a ribosome binding site into the pURA-Sm/M4 Vector. A ribosome binding site is designed based on the AT and trp2 ribosome binding sites described in copending U.S. patent application S.N. 166,882, filed 11 March 1988, and incorporated herein by re¬ ference. The ribosome binding site (rbs) referred to as TAT contains the upstream sequence found in the AT-rich rbs and the Clal site as found in the Trp2 rbs. The two oligonucleotides are synthesized, and isolated as previously described. The two oligonucleotides are then hybridized to form the following fragment:
Xbal Clal
5' CTAGATTATTAAAAATTAAAGAGGTATAT TAATAATTTTTAATTTCTCCATATAGC
This fragment is designed to be inserted into the restriction site of the pURA-SM/M4 vector produced by digestion with Xbal and Clal.
The pURA-Sm/M4 vector is digested with Xbal and Clal and the large vector fragment is purified as described above. The purified vector fragment is ligated to the TAT rbs and the ligation product is used to transform competent cells of E. coli MC1000. The resultant vector is sequenced for confirmation and is designated pURA-Sm/TAT/- M4. EXAMPLE 2. BSt Expression Using an Expression Vector Comprising a Serratia marcescens trp Promoter
The pURA-Sm/TAT/M4 vector from Example 1 is used to transformed competent cells of BST-1C (PCT/US 88/00328) . The induction protocol was previously described (PCT/US 88/00328). The results of scanning of Coomassie stained protein gel showed the vector to express rbSt at a level of about 20% of the total protein.
EXAMPLE 3. Porcine and Ovine Somatotropin Expression Using an Expression Vector Comprising a Serratia marcescens trp Promoter
Following the teachings of Examples 1 and 2 with minor changes known to those skilled in the art, the porcine or ovine somatotropin gene can also be expressed under the control of the Serratia marces¬ cens trp promoter.
Claims
1. A recombinant DNA molecule comprising a sequence of deoxyribo- nucleotides encoding a somatotropin and a Serratia marcescens trp promoter operatively linked thereto.
2. A recombinant DNA molecule according to claim 1, wherein the somatotropin is selected from porcine, ovine and bovine somatotropin.
3. A recombinant DNA molecule according to claim 2, wherein the somatotropin is bovine somatotropin.
4. A recombinant DNA molecule according to claim 3, pURA-Sm/TAT/M4.
5. A method for producing an animal somatotropin comprising cultur- ing a host transformed with a recombinant DNA molecule according to claim 1, and isolating said somatotropin from said culture.
6. A method for producing an somatotropin comprising culturing a host transformed with a recombinant DNA molecule according to claim
2, and isolating said somatotropin from said culture.
7. A method for producing bovine somatotropin comprising culturing a host transformed with a recombinant DNA molecule according to claim
3, and isolating said somatotropin from said culture.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26702788A | 1988-11-04 | 1988-11-04 | |
US267,027 | 1988-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990005186A1 true WO1990005186A1 (en) | 1990-05-17 |
Family
ID=23017012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1989/003854 WO1990005186A1 (en) | 1988-11-04 | 1989-09-12 | Somatotropin expression using a serratia promoter |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4315089A (en) |
WO (1) | WO1990005186A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112055752A (en) * | 2019-02-26 | 2020-12-08 | Cj第一制糖株式会社 | Novel promoter and method for producing purine nucleotide using the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0115613A2 (en) * | 1982-12-24 | 1984-08-15 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | DNA sequences, their preparation, plasmids containing these sequences and their use in the synthesis of eukaryotic gene products in prokaryotes |
WO1988006186A2 (en) * | 1987-02-19 | 1988-08-25 | The Upjohn Company | cDNAs ENCODING SOMATOTROPIN, EXPRESSION VECTORS AND HOSTS |
-
1989
- 1989-09-12 AU AU43150/89A patent/AU4315089A/en not_active Abandoned
- 1989-09-12 WO PCT/US1989/003854 patent/WO1990005186A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0115613A2 (en) * | 1982-12-24 | 1984-08-15 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | DNA sequences, their preparation, plasmids containing these sequences and their use in the synthesis of eukaryotic gene products in prokaryotes |
WO1988006186A2 (en) * | 1987-02-19 | 1988-08-25 | The Upjohn Company | cDNAs ENCODING SOMATOTROPIN, EXPRESSION VECTORS AND HOSTS |
Non-Patent Citations (1)
Title |
---|
Methods in Enzymology, Vol. 101, 1983, Academic Press, Inc., B.P. NICHOLS et al.: "Plasmids Containing the TRP Promoters of Escherichia Coli and Serratia Marcescens and their use in Expressing Cloned Genes", pages 155-164 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112055752A (en) * | 2019-02-26 | 2020-12-08 | Cj第一制糖株式会社 | Novel promoter and method for producing purine nucleotide using the same |
Also Published As
Publication number | Publication date |
---|---|
AU4315089A (en) | 1990-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brosius | Toxicity of an overproduced foreign gene product in Escherichia coli and its use in plasmid vectors for the selection of transcription terminators | |
EP0136490B1 (en) | Dna plasmids | |
EP0075444A2 (en) | Methods and products for facile microbial expression of DNA sequences | |
EP0131843B1 (en) | Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods | |
Fleer et al. | Stable multicopy vectors for high–level secretion of recombinant human serum albumin by Kluyveromyces Yeasts | |
RU2129606C1 (en) | STRAIN ESCHERICHIA COLI JM 105 TRANSFORMED WITH PLASMID PAE12 - PRODUCER OF ALPHA-AMIDATING ENZYME, RECOMBINANT PLASMID PAE12, MURINE CELLULAR LINE C127 TRANSFORMED WITH PLASMID PDBPV-MMTNEO α - PRODUCER OF ALPHA-AMIDATING ENZYME, RECOMBINANT PLASMID PDBPV-MMTNEO α | |
EP0047600B1 (en) | Bovine pre-growth and growth hormone | |
EP0136907A2 (en) | A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom | |
EP0103395A2 (en) | DNA sequences, recombinant DNA molecules and processes for producing bovine growth hormone-like polypeptides in high yield | |
EP0067540A2 (en) | Microbial gene promoter/operators | |
IE80663B1 (en) | Method for obtaining biologically active bovine and porcine growth hormone and composition comprising biologically active porcine growth hormone | |
US4795706A (en) | Novel expression control sequences | |
EP0409098B1 (en) | The expression and secretion of mature human beta interleukin-1 in bacillus subtilis and means and methods for its achievement | |
EP0321940B1 (en) | An improved method for the preparation of natural human growth hormone in pure form | |
US5063158A (en) | Recombinant DNA expression vector comprising both transcriptional and translational activating sequences | |
EP0306673A1 (en) | A method for the preparation of human growth hormone | |
EP0218651B1 (en) | A dna sequence | |
US5254463A (en) | Method for expression of bovine growth hormone | |
WO1990005186A1 (en) | Somatotropin expression using a serratia promoter | |
Olsen et al. | Enhancement of heterologous polypeptide expression by alterations in the ribosome-binding-site sequence | |
US4880910A (en) | Terminal methionyl bovine growth hormone and its use | |
EP0387457A1 (en) | Recombinant fish hormone proteins | |
Schoner et al. | [25] Expression of eukaryotic genes in Escherichia coli with a synthetic two-cistron system | |
US5268284A (en) | Ribosome binding site | |
WO1986005805A1 (en) | A dna sequence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1989910494 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI HU JP KR NO SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1989910494 Country of ref document: EP |